{"id":"W4361959809","doi":"10.1158/1078-0432.c.6529533","title":"Data from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Astellas Pharma; Pfizer","keywords":"Enzalutamide; Medicine; Cohort; Exemestane; Internal medicine; Population; Breast cancer; Placebo; Clinical endpoint; Oncology; Gastroenterology; Endocrinology; Prostate cancer; Cancer; Randomized controlled trial; Androgen receptor; Aromatase; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002049508,0.001209891,0.005900478,0.0004028242,0.0001716176,0.000092696,0.0007037619,0.0004084358,0.001202363],"category_scores_gemma":[0.0008442304,0.00068402,0.0002220133,0.000494515,0.0004709987,0.0003568851,0.001070138,0.001438501,0.00001716003],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009758558,"about_ca_system_score_gemma":0.0027131,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006777789,"about_ca_topic_score_gemma":0.003841607,"domain_scores_codex":[0.992497,0.0009506161,0.001689137,0.00219221,0.001852307,0.0008187791],"domain_scores_gemma":[0.9932764,0.001799608,0.00154918,0.002127733,0.0009022701,0.0003448311],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.975656,0.001928272,0.0009366436,0.00009062493,0.00537619,0.00006495998,0.001337686,0.0003732834,0.0001783611,0.000002460252,0.0001720752,0.0138834],"study_design_scores_gemma":[0.9720342,0.006262832,0.001169911,0.004236552,0.003556967,0.0000110883,0.0005155538,0.01114824,0.00003703774,0.00006312771,0.00003960897,0.0009249513],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9497958,0.0008860104,0.005831082,0.001135064,0.000664946,0.03135567,0.009716147,0.0004451957,0.0001700802],"genre_scores_gemma":[0.9232367,0.0005165515,0.03616221,0.0006777129,0.00173018,0.01423031,0.0169083,0.0006664239,0.005871595],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03033113,"threshold_uncertainty_score":0.9998361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0627104037941062,"score_gpt":0.3842795352735436,"score_spread":0.3215691314794374,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}